Dextropropoxyphene, an opioid analgesic used to treat mild to moderate pain, was developed in the 1950s and widely used in the following decades. Its history is marked by its effectiveness as a pain reliever, but also by the discovery of cardiotoxicity and risk of overdose, which led to its withdrawal or restricted use in several countries. Dextropropoxyphene, a weak opioid agonist, was included in numerous combination analgesic formulations with acetaminophen or aspirin to enhance pain relief. Its development featured extensive clinical evaluation for efficacy and safety, but concerns over fatal respiratory and cardiac events prompted regulatory agencies to implement strict guidelines and, in some regions, complete market withdrawal.
BRAND NAMES
Darvon – widely used in the United States before withdrawal.
Doloxene – combination formulations for pain relief.
Propoxyphene – used in various countries as single-agent or combination analgesics.
MECHANISM OF ACTION
Dextropropoxyphene is a weak opioid agonist that primarily acts on mu-opioid receptors in the central nervous system to produce analgesia. By binding to these receptors, it modulates pain perception and alters the emotional response to pain, providing relief from mild to moderate pain. Unlike stronger opioids, dextropropoxyphene has less pronounced respiratory depression and euphoria, but its analgesic effect is relatively modest.
PHARMACOKINETICS
Absorption
Dextropropoxyphene is rapidly and almost completely absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations are typically reached within 1 to 2 hours. Food intake may slightly delay absorption, but it does not significantly affect the overall bioavailability.
Distribution
Dextropropoxyphene has a moderate volume of distribution, approximately 2–3 L/kg, indicating that it distributes widely into body tissues, including the liver, lungs, kidneys, and muscles. It is highly lipophilic, which facilitates penetration into the central nervous system to exert its analgesic effects.
Metabolism
Dextropropoxyphene is extensively metabolized in the liver, primarily via CYP3A4- and CYP2D6-mediated pathways. It undergoes O-demethylation to form norpropoxyphene, an active metabolite with longer half-life and weaker analgesic but significant cardiotoxic properties.
Elimination
Dextropropoxyphene and its metabolites are primarily excreted via the kidneys, with approximately 70–80% of the dose recovered in urine within 24–48 hours. A smaller fraction is eliminated in feces.
PHARMACODYNAMICS
Dextropropoxyphene produces analgesia primarily through mu-opioid receptor agonism in the central nervous system, which alters pain perception and the emotional response to pain. Its pharmacodynamic profile is characterized by mild to moderate pain relief, with weaker respiratory depression and euphoria compared to stronger opioids.
ADMINISTRATION
Dextropropoxyphene is administered orally, typically in the form of tablets or capsules, either as a single agent or in combination with non-opioid analgesics such as acetaminophen or aspirin. Standard practice involves scheduled dosing for mild to moderate pain, with careful attention to maximum daily limits to reduce the risk of toxicity.
DOSAGE AND STRENGTH
Dextropropoxyphene was commonly available in oral tablet form, typically at 65 mg per tablet for single-agent formulations. When combined with acetaminophen, tablets usually contained 32.5 mg dextropropoxyphene with 325 mg acetaminophen.
DRUG INTERACTIONS
Dextropropoxyphene can interact with several drugs due to its central nervous system depressant and cardiotoxic properties. Concomitant use with other opioids, benzodiazepines, alcohol, or sedatives can lead to enhanced sedation, respiratory depression, and CNS depression.
FOOD INTERACTIONS
Food intake may slightly delay the absorption of orally administered dextropropoxyphene, but it does not significantly affect overall bioavailability or analgesic efficacy. Therefore, the medication can be taken with or without food.
CONTRAINDICATIONS
Dextropropoxyphene is contraindicated in patients with a known hypersensitivity to the drug or other opioids. It should not be used in individuals with significant respiratory depression, acute asthma, or paralytic ileus, as its opioid effects can exacerbate these conditions.
SIDE EFFECTS
Drowsiness or sedation
Dizziness or lightheadedness
Nausea and vomiting
Constipation
Dry mouth
Headache
Respiratory depression
Cardiac arrhythmias
Hypotension
Allergic reactions.
OVER DOSAGE
Overdosage of dextropropoxyphene is potentially life-threatening and is characterized by central nervous system depression, respiratory depression, and serious cardiac toxicity. Symptoms may include extreme drowsiness, coma, slow or shallow breathing, hypotension, and cardiac arrhythmias, particularly due to accumulation of its toxic metabolite, norpropoxyphene.
TOXICITY
Dextropropoxyphene toxicity is primarily associated with its central nervous system depressant effects and cardiotoxic potential. Overdose can lead to respiratory depression, severe sedation, hypotension, and coma. Its active metabolite, norpropoxyphene, contributes significantly to cardiac conduction abnormalities, including prolonged QT interval and potentially fatal arrhythmias.
